MUC1 and cancer: In conclusion, we have successfully engineered and validated rAdF35-MUC1, a novel adenovirus that detects CTCs in the blood of cancer patients with high sensitivity and specificity, offering a promising tool for early diagnosis and monitoring treatment efficacy.